Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Gains from Sales and Divestitures (2023 - 2025)

Amylyx Pharmaceuticals (AMLX) has 3 years of Gains from Sales and Divestitures data on record, last reported at $1.2 million in Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures rose 68.82% year-over-year to $1.2 million; the TTM value through Dec 2025 reached $1.2 million, up 68.82%, while the annual FY2025 figure was $1.2 million, 68.82% up from the prior year.
  • Gains from Sales and Divestitures reached $1.2 million in Q4 2025 per AMLX's latest filing, up from $1.2 million in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $1.2 million in Q4 2025 and bottomed at $146694.0 in Q1 2023.
  • Average Gains from Sales and Divestitures over 3 years is $534057.0, with a median of $477789.5 recorded in 2024.
  • The widest YoY moves for Gains from Sales and Divestitures: up 306.16% in 2024, down 57.77% in 2024.
  • A 3-year view of Gains from Sales and Divestitures shows it stood at $185045.0 in 2023, then skyrocketed by 284.89% to $712218.0 in 2024, then soared by 68.82% to $1.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $1.2 million in Q4 2025, $1.2 million in Q3 2025, and $775162.0 in Q2 2025.